for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Genus plc

GNS.L

Latest Trade

3,146.00GBp

Change

36.00(+1.16%)

Volume

83,891

Today's Range

3,102.00

 - 

3,152.00

52 Week Range

2,090.00

 - 

3,170.08

As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay

Pricing

Previous Close
3,110.00
Open
3,134.00
Volume
83,891
3M AVG Volume
1.68
Today's High
3,152.00
Today's Low
3,102.00
52 Week High
3,170.08
52 Week Low
2,090.00
Shares Out (MIL)
65.07
Market Cap (MIL)
1,952.11
Forward P/E
37.96
Dividend (Yield %)
--

Next Event

Genus PLC Annual Shareholders Meeting

Latest Developments

More

Genus Says Jury In U.S. District Court Considered Damages In IntelliGen Litigation

Genus Says On Jury In US Court Held That Genus' Sexing Semen Technology Infringed Three Patents Asserted By Inguran, Llc And Cytonome

Genus FY Rev, Pretax Profit Rise

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Genus plc

Genus plc is an animal genetics company, which provides farmers with genetics that enable them to produce animal protein, in the form of meat and milk. The Company's segments include Genus PIC, Genus ABS, Genus Asia, and Research and Development. The Genus PIC segment is engaged in porcine sales business, excluding Asia, and serves porcine customers in North America, Latin America and Europe. The Genus ABS segment is engaged in bovine sales business, excluding Asia, and serves dairy and beef customers in North America, Latin America and Europe. The Genus Asia segment is engaged in porcine and bovine business in Asia, and serves porcine, dairy and beef customers in Asian markets. In the porcine market, it sells boars and sows. In the dairy and beef markets, its primary product is bull semen. The Company offers embryos through its subsidiary, In Vitro Brasil S.A. Its porcine business has a network of over 600 breeding herds in approximately 40 countries.

Industry

Biotechnology & Drugs

Contact Info

Matrix House, Basing View

+44.1256.347100

https://www.genusplc.com

Executive Leadership

Robert A. Lawson

Non-Executive Independent Chairman of the Board

Stephen Wilson

Chief Executive, Executive Director

Janet Duane

Interim Group Finance Director

Elena Rice

Chief Scientific Officer and Head of Research and Development

Dan Hartley

Group General Counsel & Company Secretary

Key Stats

2.17 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, GBP)

2017

0.5K

2018

0.5K

2019

0.5K

2020(E)

0.5K
EPS (GBp)

2017

68.400

2018

74.900

2019

70.700

2020(E)

79.030
Price To Earnings (TTM)
298.54
Price To Sales (TTM)
4.00
Price To Book (MRQ)
3.88
Price To Cash Flow (TTM)
59.15
Total Debt To Equity (MRQ)
21.86
LT Debt To Equity (MRQ)
21.01
Return on Investment (TTM)
0.97
Return on Equity (TTM)
0.83

Latest News

Latest News

Medical device maker ConvaTec names Genus top boss as CEO

British medical devices maker ConvaTec Group Plc on Monday named Genus Plc's top boss Karim Bitar as its chief executive officer and said Chairman Christopher Gent would retire from his role.

Medical device maker ConvaTec names Karim Bitar CEO

British medical devices maker ConvaTec Group Plc on Monday named Genus Plc's top boss Karim Bitar as its chief executive officer and said Chairman Christopher Gent would retire from his role.

ConvaTec to appoint Karim Bitar from Genus as CEO - Sky News

Catheter and colostomy bag maker ConvaTec Group Plc will on Monday appoint Karim Bitar as the company's chief executive officer, and will announce the departure of its Chairman Christopher Gent, Sky News reported on Sunday.

BRIEF-Genus Plc Reports HY ‍basic Earnings Per Share of 69 Pence​

* HY ADJUSTED PROFIT BEFORE TAX 29.0 MILLION POUNDS VERSUS 25.1 MILLION POUNDS AS REPORTED YEAR- AGO

BRIEF-Genus sees performance in line with growth expectations for 2018​

* GENUS - TRADING WAS IN LINE WITH EXPECTATIONS IN PERIOD FROM 1 JULY TO 15 NOV 2017 AND CONTINUED TO MAKE GOOD PROGRESS TOWARDS ITS STRATEGIC OBJECTIVES FOR YEAR

BRIEF-Genus comments on NMR proposed withdrawal from Milk Pension Fund

* Draws attention to announcement made today by national Milk Records Plc on NEX Exchange Growth Market

BRIEF-Genus awarded injunction in litigation against Inguran LLC

* Announces injunction awarded in favour in connection with litigation against Inguran LLC, operating as Sexing Technologies Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

BRIEF-KBJ to acquire stake in Albit Software

* Says signs deal with ALBIT Software - Arkadiusz Lućko (AL) and GNS Systemy Informatyczne - Norbert Gredka (GNS) to form Albit Software Sp. z o.o. (Albit)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up